Liu Yawen, Feng Wen, Liu Wenyu, Kong Xiangyu, Li Lei, He Junbo, Wang Dawei, Zhang Meiting, Zhou Gai, Xu Wei, Chen Wei, Gong Aihua, Xu Min
Department of Gastroenterology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China.
Department of Gastroenterology, Songjiang Hospital Affiliated Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai 201600, China.
J Cancer. 2019 Jun 9;10(16):3746-3756. doi: 10.7150/jca.32052. eCollection 2019.
: Recent studies have shown that circulating long noncoding RNAs (lncRNAs) could be stably detectable in the blood of cancer patients and play important roles in the diagnosis of many different cancers. However, the value of lncRNAs in the diagnosis of pancreatic cancer (PC) has not been fully explored. : Eleven PC-related lncRNAs were selected by analyzing bioinformatics databases. The expression levels of the lncRNAs were further analyzed in a small set of plasma samples from a training group including 30 noncancer samples (15 healthy and 15 chronic pancreatitis (CP) subjects) and 15 PC samples. Then, the candidate lncRNAs were validated with data from 46 healthy controls, 97 CP patients and 114 PC patients. Receiver operating characteristic (ROC) curves were employed to evaluate the diagnostic performance of the identified lncRNAs. : After selection and validation, three characteristic plasma candidate lncRNAs, ABHD11-AS1, LINC00176 and SNHG11, were identified, and their levels were significantly higher in PC patients than in normal controls. We found that among the three candidate lncRNAs, ABHD11-AS1 showed the best diagnostic performance for the detection of PC. Furthermore, ABHD11-AS1 had a higher area under the ROC curve (AUC) than CEA, CA199 and CA125 for early PC diagnosis, while the combination of ABHD11-AS1 and CA199 was more effective than ABHD11-AS1 alone. : Plasma ABHD11-AS1 could serve as a potential biomarker for detecting PC, and the combination of ABHD11-AS1 and CA199 was more efficient for the diagnosis of PC than ABHD11-AS1 alone, particularly for early tumor screening.
近期研究表明，循环长链非编码RNA（lncRNAs）在癌症患者血液中可稳定检测到，并在多种不同癌症的诊断中发挥重要作用。然而，lncRNAs在胰腺癌（PC）诊断中的价值尚未得到充分探索。
通过分析生物信息学数据库筛选出11种与PC相关的lncRNAs。在一个训练组的少量血浆样本中进一步分析这些lncRNAs的表达水平，该训练组包括30个非癌样本（15名健康受试者和15名慢性胰腺炎（CP）患者）以及15个PC样本。然后，用来自46名健康对照、97名CP患者和114名PC患者的数据对候选lncRNAs进行验证。采用受试者工作特征（ROC）曲线评估所鉴定lncRNAs的诊断性能。
经过筛选和验证，鉴定出三种特征性血浆候选lncRNAs，即ABHD11-AS1、LINC00176和SNHG11，它们在PC患者中的水平显著高于正常对照。我们发现，在这三种候选lncRNAs中，ABHD11-AS1在PC检测中表现出最佳的诊断性能。此外，对于早期PC诊断，ABHD11-AS1的ROC曲线下面积（AUC）高于癌胚抗原（CEA）、糖类抗原199（CA199）和糖类抗原125（CA125），而ABHD11-AS1与CA199联合使用比单独使用ABHD11-AS1更有效。
血浆ABHD11-AS1可作为检测PC的潜在生物标志物，ABHD11-AS1与CA199联合用于PC诊断比单独使用ABHD11-AS1更有效，特别是对于早期肿瘤筛查。
